Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).

Christopher F Bell Priyanka Jain Raj Desai Daniel C Gibbons Myriam Drysdale Maral DerSarkissian Vishal Patel Helen J BirchEmily J LloydAdina Zhang Mei Sheng Duhnull null

Published in: Clinical drug investigation (2024)

Sotrovimab demonstrated clinical effectiveness in preventing severe outcomes (hospitalisation, mortality) in the period 27 September 2021-30 April 2022, which included Delta and Omicron BA.1 variants and an early surge of Omicron BA.2 variant.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review
quality improvement
cardiovascular events
respiratory syndrome coronavirus
early onset
copy number
risk factors
type diabetes
cardiovascular disease
adipose tissue
skeletal muscle
genome wide
replacement therapy